ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.
Clin Cancer Res. 2017 Feb 15;23(4):992-1000. doi: 10.1158/1078-0432.CCR-16-1568. Epub 2016 Aug 29.
Clin Cancer Res. 2017.
PMID: 27573171